Shares of Kymera Therapeutics, Inc. (NASDAQ: KYMR – Get Rating) gapped up prior to trading on Friday. The stock had previously closed at $ 14.25, but opened at $ 14.99. Kymera Therapeutics shares last traded at $ 15.27, with a volume of 1,768 shares traded.
A number of equities research analysts recently issued reports on the company. Wells Fargo & Company lowered their price objective on Kymera Therapeutics from $ 62.00 to $ 35.00 and set an “overweight” rating on the stock in a research report on Wednesday, June 1st. Morgan Stanley lowered their price objective on Kymera Therapeutics from $ 68.00 to $ 66.00 and set an “equal weight” rating on the stock in a research report on Wednesday, March 2nd. Piper Sandler lowered their price objective on Kymera Therapeutics from $ 91.00 to $ 43.00 and set an “overweight” rating on the stock in a research report on Monday, May 23rd. B. Riley lowered their price objective on Kymera Therapeutics from $ 67.00 to $ 50.00 in a research report on Wednesday, May 4th. Finally, Credit Suisse Group started coverage on Kymera Therapeutics in a research note on Thursday, April 28th. They issued an “outperform” rating and a $ 63.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, Kymera Therapeutics currently has an average rating of “Buy” and an average target price of $ 64.18.
The stock has a 50 day moving average price of $ 22.25 and a 200-day moving average price of $ 37.38. The stock has a market capitalization of $ 815.62 million, a P / E ratio of -6.36 and a beta of 2.30.
Kymera Therapeutics (NASDAQ: KYMR – Get Rating) last announced its quarterly earnings data on Tuesday, May 3rd. The company reported ($ 0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($ 0.67) by ($ 0.04). Kymera Therapeutics had a negative net margin of 194.23% and a negative return on equity of 30.40%. The company had revenue of $ 9.62 million for the quarter, compared to the estimate consensus of $ 18.66 million. During the same period last year, the business posted ($ 0.29) earnings per share. The firm’s quarterly revenue was down 48.6% compared to the same quarter last year. Sell-side analysts expect that Kymera Therapeutics, Inc. will post -2.58 EPS for the current year.
In other Kymera Therapeutics news, Director Bvf Partners L. P / Il bought 10,100 shares of the business’s stock in a transaction that occurred on Friday, May 20th. The shares were bought at an average cost of $ 14.00 per share, with a total value of $ 141,400.00. Following the completion of the purchase, the director now directly owns 2,036,860 shares of the company stock, valued at $ 28,516,040. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bvf Partners L. P / Il bought 224,057 shares of the business’s stock in a transaction that occurred on Thursday, May 26th. The stock was acquired at an average cost of $ 14.21 per share, for a total transaction of $ 3,183,849.97. Following the completion of the purchase, the director now directly owns 2,159,903 shares of the company stock, valued at $ 30,692,221.63. The disclosure for this purchase can be found here. Insiders have bought 384,157 shares of company stock worth $ 6,265,250 over the last ninety days. Insiders own 23.28% of the company stock.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. grew its stake in shares of Kymera Therapeutics by 0.6% in the first quarter. BlackRock Inc. now owns 3,419,084 shares of the company stock worth $ 144,698,000 after purchasing an additional 21,544 shares during the last quarter. Wellington Management Group LLP lifted its holdings in Kymera Therapeutics by 19.7% in the first quarter. Wellington Management Group LLP now owns 3,225,749 shares of the company stock worth $ 136,514,000 after buying an additional 530,935 shares during the period. State Street Corp lifted its holdings in Kymera Therapeutics by 27.6% in the first quarter. State Street Corp now owns 2,094,561 shares of the company stock worth $ 88,642,000 after buying an additional 452,799 shares during the period. Rock Springs Capital Management LP lifted its holdings in Kymera Therapeutics by 1.9% in the first quarter. Rock Springs Capital Management LP now owns 755,875 shares of the company stock worth $ 31,989,000 after buying an additional 13,810 shares during the period. Finally, Bank of New York Mellon Corp lifted its holdings in Kymera Therapeutics by 29.3% in the first quarter. Bank of New York Mellon Corp now owns 686,194 shares of the company stock worth $ 29,041,000 after buying an additional 155,476 shares during the period. 77.73% of the stock is currently owned by institutional investors.
About Kymera Therapeutics: (NASDAQ: KYMR)
Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing the IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammatory diseases, including suppurative hydradenitis, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
Receive News & Ratings for Kymera Therapeutics Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Kymera Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.